If You’re Short On Time:
DTC marketing has evolved. Those DTC managers who use the exact roadmap will waste a lot of money when accountability is increasing. Challenges await, and there isn’t one set of guidelines for every product category.
Every year, pharmaceutical companies contribute millions of dollars to U.S. senators and representatives as part of a multipronged effort to influence health care lawmaking and spending priorities. For example, Sen. Tim Scott, a rising star in the Republican Party with broad popularity in South Carolina, is getting showered with drug industry money before facing voters this fall.
After two years of pandemic fatigue, healthcare trust is at an all-time low, according to Edelman’s Trust Barometer Special Report on Trust in Healthcare. Still, the report may be too generalized for every healthcare player.
Bristol Myers Squibb Co was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019. Was it a wise move or incompetence?
COVID may be winding down, but the damage is done in deaths and long COVID. We don’t understand much, but we do know that there is a correlation between COVID severity and obesity/diabetes. The question thus becomes, “will the medical community finally address the obesity epidemic, or will we continue to do nothing essentially?”.
According to STAT News “after a double-digit decline in 2021, the sector has fallen another 20% in the new year, erasing billions in value and leading even the most seasoned investors to question whether biotech has further to fall. Can small biotech companies survive?
This is an exciting time to be in healthcare marketing. We’re witnessing the most significant transformation in healthcare marketing since DTC was approved in the ’90s. We’re moving from an era of “promotional marketing” to an age of “data is key” and “helping patients become consumers of healthcare.”